Recombinant KLK1: the next step in stroke and preeclampsia treatment
With its lead candidate DM199, DiaMedica Therapeutics is advancing a recombinant form of KLK1 to res...
Flößergasse 481369 MünchenGermany
Our mission at NanoTemper Technologies is to create biophysical tools for scientists in drug discovery and development who need to tackle challenging characterizations. Working with scientists striving to make a difference in the world gets us excited. If you’re facing challenges with affinity screening, molecular interactions or protein stability let’s talk.
With its lead candidate DM199, DiaMedica Therapeutics is advancing a recombinant form of KLK1 to res...
New research has discovered a key survival mechanism in metastatic melanoma, revealing that cancer c...
Researchers have discovered that pancreatic tumours evade the immune system by disguising themselves...
Unlock Exclusive Industry Insights